Title : Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.

Pub. Date : 2013 Sep

PMID : 23256542






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Abstract This phase I study was conducted to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the heat shock protein 90 (HSP90) inhibitor 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib, and to provide pharmacokinetic data in relapsed or refractory acute myeloid leukemia (AML). Bortezomib heat shock protein 90 alpha family class A member 1 Homo sapiens